Biotech Stock News (RXII) (GNCA)

Rxi Pharmaceuticals (NASDAQ:RXII) On Thursday March 31, 2016 Rxi Pharmaceuticals announced that it had received a patent from the United States Patent and Trademark Office — USPTO — for the company’s sd-rxRNA technology platform that covers CTGF — Connective Tissue Growth Factor. In essence the patent covers the company’s lead clinical product RXI-109, which is … Read more

Biotech Stock News (ACAD) (RXII) (REGN) (AZN) (ZSPH)

Acadia Pharmaceuticals (NASDAQ:ACAD) On November 3, 2015 Acadia had announced that the FDA had given its Parkinson’s Drug, NUPLAZID, FDA priority review. To understand what this means, we must first understand what the FDA priority review actually means? A company is only given FDA priority review if the drug it has developed treats an unmet … Read more

Biotech Stock News (RXII) (MRK) (BMY) (CNAT) (ICPT)

Rxi Pharmaceuticals Corp (NASDAQ: RXII) Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported ┬ápositive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. … Read more